SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!!
IGT 16.66+0.4%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Spiney who wrote (51)1/12/1999 10:38:00 AM
From: Stephen O   of 86
 
I'll check with them later but I am sure that both trials will run simultaneously, they have enough of the drug on hand. You're right the US with the FDA is the big one. They are using a new PR group Tandem Capital group. In their news release, from Tandem, they quote a study done by Ernst & Young that biotech companies on average with a phase 1 trial had a market cap of $100 million, for phase 1 cancer drugs the average number is $52 million. Compare that to IGT's mkt cap of about $8 million. We have a long way to go.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News